Akebia Therapeutics Inc (NASDAQ: AKBA) open the trading on Wednesday, with a bit cautious approach as it glided -32.04% to $2.1, before settling in for the price of $3.09 at the close. Taking a more long-term approach, AKBA posted a 52-week range of $1.52-$4.08.
It was noted that the giant of the Healthcare sector posted annual sales growth of 32.58% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 32.58%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 100.39%. This publicly-traded company’s shares outstanding now amounts to $263.04 million, simultaneously with a float of $254.74 million. The organization now has a market capitalization sitting at $556.80 million. At the time of writing, stock’s 50-day Moving Average stood at $2.93, while the 200-day Moving Average is $2.77.
Akebia Therapeutics Inc (AKBA) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Drug Manufacturers – Specialty & Generic industry. Akebia Therapeutics Inc’s current insider ownership accounts for 3.92%, in contrast to 41.67% institutional ownership. According to the most recent insider trade that took place on Jun 30 ’25, this organization’s SVP, CFO, CBO & Treasurer sold 41,314 shares at the rate of 3.67, making the entire transaction reach 151,622 in total value, affecting insider ownership by 503,586.
Akebia Therapeutics Inc (AKBA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
Akebia Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 100.39% and is forecasted to reach 0.12 in the upcoming year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Let’s observe the current performance indicators for Akebia Therapeutics Inc (AKBA). It’s Quick Ratio in the last reported quarter now stands at 1.84. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.73.
In the same vein, AKBA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.17, a figure that is expected to reach -0.02 in the next quarter, and analysts are predicting that it will be 0.12 at the market close of one year from today.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
[Akebia Therapeutics Inc, AKBA] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 55.05% While, its Average True Range was 22.83.
Raw Stochastic average of Akebia Therapeutics Inc (AKBA) in the period of the previous 100 days is set at 1.00%, which indicates a major fall in contrast to 1.79% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.17 that was higher than 0.16 volatility it exhibited in the past 100-days period.
